Sara Rogers, Director of the American Society of Pharmacovigilance (ASP) and Co-Chairman of the Pharmacogenomics Access and Reimbursement Coalition (PARC) joined us in this episode of Precision Insights to discuss the past, present and future of reimbursement for pharmacogenomics.
Sara leads clinical programs at the American Society of Pharmacovigilance (ASP), which is designed to build bridges between groups, ideas and individuals to rapidly and dramatically reduce the high rate of suffering and mortality due to adverse drug events in the U.S.
She co-chairs the Pharmacogenomics Access & Reimbursement Coalition to address payer issues and the barriers posed for widespread implementation of pharmacogenetic testing, which is known to be a significant player in proactively addressing medication side effects.
Related to ASP and PARC, Sara also co-developed the Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Initiative, a public-private multidisciplinary collaborative community to accelerate the development of personalized medicine practices as a standard of care. An initiative which is now recognized by the U.S Food & Drug Administration.
Read more here:
Melissa Badowski, Clinical Associate Professor and Clinical Pharmacist in HIV/Telemedicine for the University of Illinois at Chicago College of Pharmacy, joined us in this episode of Precision Insights to talk about her experience working as part of an inter-professional care team and using telehealth to deliver comprehensive medication management to vulnerable populations.
Dr Badowski manages patients with HIV in the Illinois Department of Corrections through telemedicine services as well as in the outpatient setting and through transitions in care. She is also the Founding Chair of the American College of Clinical Pharmacy’s HIV Practice and Research Network.
Jared Augenstein, Director of Manatt Health, joined us in this episode of Precision Insights to talk about the reimbursement trends for digital health, the limits of telehealth/virtual care and the exciting opportunities it presents, and differentiating innovations that will improve outcomes, quality, and cost from those that won’t.
Jared’s primary areas of focus are advising public- and private-sector clients on delivery system transformation, population health, digital health, international and global health, federal and state health policy trends and provider markets.
Read more here: https://www.manatt.com/jared-augenstein
James Lu, Co-founder and Chief Scientific Officer, Helix, joined us to talk about the current state of genetics use in patient-centered care, the critical elements for successful large-scale genomics initiatives, and a vision to improve care delivery for life with reusable genetic information.
Dr. Lu co-founded population genomics company Helix in 2015, where he leads the research, regulatory, policy, and bioinformatics teams. Dr. Lu oversees the teams that develop and validate the science and technology behind Helix’s solutions, including Helix’s CLIA / CAP NGS lab. Dr. Lu also works with Helix’s partners to design and execute population-scale genomic research initiatives.
Learn more about Helix: https://www.helix.com/
Erik Abel, VP Insights, Ursa Health & former Director of Clinical Transformation, Highmark Health, joined us to talk about ways to leverage data & technology to help clinicians make optimized treatment decisions, move towards a truly informed prescribing, and to manage system-level changes in healthcare.
Erik is a subject matter expert in clinical operations, health IT and pharmacotherapeutics, driving strategic development, deploying transformative health and wellness services, and supporting new reimbursement approaches.
Adrijana Kekic, Pharmacogenomics Pharmacist and Associate Program Director for Outpatient Pharmacy at Mayo Clinic, joined us to talk about the role of pharmacists in delivering personalized care and the ways that technology is enabling PGx implementation at the point of care. She also discussed some challenges and opportunities in this exciting field of personalized medicine.
Adrijana has more than two decades of pharmacy leadership and clinical expertise in personalized medication therapy management, Adrijana continues to advance pharmacy practice. She is a founder of a networking platform dedicated to high impact professional women in healthcare.
Richard (Curt) Dame, Vice President of Aon Health Solutions Practice, joined us to talk about the deployment of pharmacogenomics into popular health management programs, the successes he has seen through the members’ health outcomes, and the future he thinks it has.
Curt has more than 30 years of experience in the management, design, administration, compliance, funding, and communication of employee benefit programs.
With 25+ years of experience in pharmacy and healthcare IT consulting, he started FusionRx, a company that aims to fuse all data to provide individuals with personalized medication plans and make pharmacy a better practice.
Learn more about FusionRx: https://www.fusionrx.com/
Sue Paul, Founder and CEO of SyneRxgy Consulting, PGx101 and Medipreneurs, joined us to talk about her experience implementing pharmacogenetic (PGx) information into the point of care and educating patients and healthcare providers about the principles and implications of PGx in primary care.
Sue has over 20 years of experience working as a clinical pharmacist. She started three businesses to help solve healthcare’s pressing issues, bridge the gap in primary care and connect like-minded care providers together to fix the broken healthcare systems.
Learn more about her businesses here:
SyneRxgy Consulting: www.synerxgy.com
Medipreneurs Summit: www.medipreneurs.com
PGx101 Education: www.pgx101.com
In this episode, she discusses how her team is helping employers make informed decisions on healthcare strategy, address common health issues in the workplace and embrace the emergence of precision medicine.
Danny Sands MD, MPH of Beth Israel Deaconess Medical Center joined us to talk about how our health care system is not working as well as it should for patients and clinicians, nor for the government, employers, and insurance plans that pay for it. We can do better by taking better advantage of technology, combined with the sociological change of viewing health care as a partnership rather than a one-sided chore. Patients and clinicians should be partners.
Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. For over twenty years he has worked at the intersection of health care, technology, and business.
It was Tom’s vision and leadership that resulted in the creation of IBI in 1995. Tom has guided IBI to become the leading research organization focused on health and productivity and has led to the growth of the organization to nearly 1,200 corporate members, representing more than 20 million U.S. workers.
Carrie Hurwitz Williams, Principal at McKesson Ventures, joined us for a conversation on emerging trends in precision medicine, pockets of adoption and organizations addressing business challenges facing the health care industry.
Carrie has nearly 15 years of healthcare experience from several vantage points within the healthcare industry. Prior to joining McKesson Ventures, she served as Vice President, Strategy and Business Development for San Francisco-based digital therapeutics pioneer Omada Health.
Bob Mehr is a business innovator and industry leader who began his career as a Compounding Pharmacist. Bob Mehr has been the President and CEO of Pure Integrative Pharmacy since 1999 opening 14 stores. His experience with precision prescribing goes beyond his practice and has had a tremendous impact on his own health.
‘A patient died right in front of me because they had the wrong medication. We need to stop practicing medicine like this, we need to be more precise. I opened my pharmacies because I wanted a change, and I wanted everyone to take advantage of it’ Bob Mehr, President, and CEO of Pure Integrative Pharmacy
Dr. Liam Brunham, Assistant Professor in the Department of Medicine at the University of British Columbia and a Principal Investigator at the UBC Centre for Heart and Lung Innovation join us for a conversation on adverse drug reactions, pharmacogenetics and iPSC.
Imagine being able to reprogram your cells to find the right medication for your heart. Understanding the biological and molecular processes underlying adverse drug reactions (ADRs) is fundamental to develop innovative approaches to prevent them. One of the most promising technologies to identify the genetic mechanisms behind ADRs are induced pluripotent stem cells (iPSCs).